Esomeprazole (Nexium)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease (GERD)
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Trial Timeline
Oct 1, 2004 → Oct 1, 2005
NCT ID
NCT00228527About Esomeprazole (Nexium)
Esomeprazole (Nexium) is a approved stage product being developed by AstraZeneca for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00228527. Target conditions include Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00228527 | Approved | Completed |
| NCT00241501 | Phase 3 | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease (GERD)